TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN Share Price
Certificat
DE000SU442B7
| Market Closed - Boerse Frankfurt Warrants 20:37:45 03/06/2024 BST | ||
| 9 EUR | -3.64% |
|
| Current month | -1.50% | ||
| 1 month | +2.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 9.2 | -1.50% |
| 31/05/24 | 9.34 | -2.30% |
| 30/05/24 | 9.56 | -5.16% |
| 29/05/24 | 10.08 | +3.70% |
| 28/05/24 | 9.72 | +5.88% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 08:37 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SU442B |
| ISIN | DE000SU442B7 |
| Date issued | 22/01/2024 |
| Strike | 403.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.62 € |
|---|---|
| Lowest since issue | 7.59 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.4
USD
Average target price
316.3
USD
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat